NEW FDA WARNINGS
TODAY'S HEADLINES
Soon after FDA warned about a potential increased risk of foot and leg amputations with the use of the type 2 diabetes medication canagliflozin (Invokana and Invokamet), the agency added another risk with Invokana and Invokamet, as well as with dapagliflozin (Farxiga and Xigduo). Find out why |
|
FDA is warning consumers about the risk of serious bleeding when using over-the-counter aspirin-containing antacid products to treat heartburn. The agency issued a separate warning about loperamide (Imodium), saying that abuse or misuse of the product can cause serious heart problems that can lead to death. Read more
|
CONTINUING PHARMACY EDUCATION
This month's CE activity, "The rundown: Management of acute and chronic diarrhea," is open for pharmacists and pharmacy technicians.
The goal of this activity is to review the various risk factors, etiologies, and treatments of diarrhea as well as the pharmacist's role in its management.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More
|
EDITOR'S PICK
Teva Pharmaceuticals is temporarily suspending sales and distribution of its sumatriptan iontophoretic transdermal system (Zecuity) patch for migraines, after FDA said it is investigating the risk of serious burns with the use of the patch. Read more
|
|
|
